Compass Pathways PLC ADR CMPS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Compass Pathways Appoints Kelley Boucher as Chief People Officer
-
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
-
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
-
Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
-
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
-
Compass Pathways to Participate in Investor Conferences the Week of September 14th
-
Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year
Trading Information
- Previous Close Price
- $11.95
- Day Range
- $11.63–12.07
- 52-Week Range
- $4.88–15.87
- Bid/Ask
- $11.84 / $12.01
- Shares Outstanding
- 138.48M
- Market Cap
- $1.65B
- Volume/Avg
- 3M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Stock Style Box
- —
- Total Number of Employees
- 156
- Website
- https://compasspathways.com
Valuation
|
Metric
|
CMPS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 19.19 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CMPS
|
|---|---|
Quick Ratio | 1.22 |
Current Ratio | 1.30 |
Interest Coverage | −77.21 |
Quick Ratio
CMPS
Profitability
|
Metric
|
CMPS
|
|---|---|
Return on Assets (Normalized) | −47.12% |
Return on Equity (Normalized) | −151.50% |
Return on Invested Capital (Normalized) | −112.10% |
Return on Assets
CMPS
Medical Care Facilities Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Genesis Healthcare Inc Class A
GENNQ
| LOCK|^W# | LOCK|!Y& | — | |||
| HCA Healthcare Inc
HCA
| LOCK|w#P&>^ | LOCK|BsK$X | $92B | |||
| Fresenius SE & Co KGaA ADR
FSNUY
| — | LOCK|!VS>! | $28B | |||
| Tenet Healthcare Corp
THC
| LOCK|RQXQlD | LOCK|@Z!V | $21B | |||
| Fresenius Medical Care AG
FMCQF
| — | LOCK|@SQQV | $12B | |||
| Fresenius Medical Care AG ADR
FMS
| LOCK|<Wsy^% | LOCK|@V#mY | $12B | |||
| Encompass Health Corp
EHC
| — | LOCK|<%TZH | $12B | |||
| DaVita Inc
DVA
| LOCK|!s<$<< | LOCK|Rww>p | $11B | |||
| Universal Health Services Inc Class B
UHS
| LOCK|<wL#>@ | LOCK|><^$S | $10B | |||
| Ensign Group Inc
ENSG
| — | LOCK|$bzD | $10B |
United States